Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Coupang Inc (CPNG) vs Medpace Holdings Inc (MEDP) Price & Performance

Coupang IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Coupang Inc vs Medpace Holdings Inc — how do they compare? Coupang Inc trades at $16.19 (market cap $29.34B), while Medpace Holdings Inc trades at $586.39 (market cap $16.66B). The key difference: Coupang Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals.

CPNGMEDP
Market Cap
$29.34B$16.66B
Sector
Consumer CyclicalTechnology
52-Week High
$33.53$620.59
52-Week Low
$15.12$393.42
Enterprise Value
$28.86B$16.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Coupang Inc

Coupang (CPNG) trades at $16.42, up 1.42% on the day, with technical indicators showing a neutral to bearish bias as the stock consolidates near key support levels. The company reported mixed Q2 2026 results with revenue acceleration but missed earnings expectations, while maintaining strong revenue growth trends and positive operating cash flow of $1.77 billion in 2025. Recent news highlights Coupang's debut on the Fortune Global 500 and ongoing recovery from a data breach incident.

Despite near-term earnings pressure and regulatory challenges, Coupang maintains dominant market position in South Korean e-commerce with expanding Taiwan operations. Wall Street remains overwhelmingly bullish with 87.5% buy ratings and a $23.38 consensus price target representing 42% upside potential, though investors should monitor execution on profitability targets and resolution of the $422 million regulatory fine.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Coupang Inc

Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.

Read more on CPNG

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP